Comparison of the in vitro activities of delafloxacin and comparators against Staphylococcus epidermidis clinical strains involved in osteoarticular infections: a CRIOGO multicentre retrospective study

• DOI: 10.1093/jac/dkae071
• Publication Date: 2024-03-20T16:45:46Z
• Authors: E Tessier; L Ruffier d’Epenoux; M F Lartigue; L Chaufour; C Plouzeau-Jayle; R Chenouard; F Guérin; D Tandé; C Lamoureux; P Bémer; S Corvec; ; Pierre Abgueguen; Marin Caubrière; Carole Lemarie; Rachel Chenouard; Hélène Pailhories; Amandine Vildy; Séverine Ansart; Luc Quaesaet; Eric Stindel; Didier Tandé; Claudie Lamoureux; Anaïs Greves; David Boutoille; Raphaël Lecomte; Colin Deschanvres; Christophe Nich; Vincent Crenn; Pascale Bémer; Stéphane Corvec; Louise Ruffier d’...; Axelle Paquin; Matthieu Grégoire; Céline Bourigault; Barbara Plantard; France Cazenave-R...; Gwenaël Le Moal; Pierre Pries; Chloé Plouzeau-Jayle; Céline Thomas; Cédric Arvieux; Marion Baldeyrou; Harold Common; Vincent Cattoir; Sophie Reissier; Anne Méheut; Louis Bernard; Adrien Lemaignen; Marion Lacasse; Philippe Rosset; Louis-Romée Le Nail; Marie-Frédérique ...; Isabelle Laplaige; Laura Chaufour
• Keywords: Ofloxacin; [SDV]Life Sciences [q-bio]; Moxifloxacin; Microbial Sensitivity Tests; Levofloxacin; Staphylococcal Infections; Anti-Bacterial Agents; [SDV] Life Sciences [q-bio]; 615; 616; Drug Resistance, Bacterial; Staphylococcus epidermidis; Humans; France; Fluoroquinolones; Retrospective Studies

Abstract Objectives Staphylococcus epidermidis bone and joint infections (BJIs) on material are often difficult to treat. The activity of delafloxacin has not yet been studied S. in this context. aim study was assess its vitro compared with other fluoroquinolones, against a large collection clinical strains. Methods We selected 538 strains isolated between January 2015 February 2023 from six French teaching hospitals. One hundred fifty-two were ofloxacin susceptible 386 resistant. Identifications performed by MS MICs determined using gradient concentration strips for ofloxacin, levofloxacin, moxifloxacin delafloxacin. Results Ofloxacin-susceptible all fluoroquinolones. Resistant had higher Strains resistant (89.1%) still showed susceptibility when the aureus 2021 CA-SFM/EUCAST threshold 0.25 mg/L. In contrast, only 3.9% ofloxacin-resistant remained 0.016 mg/L breakpoint according guidelines 2022. MIC50 0.094 MIC90 0.38 Conclusions low ofloxacin-susceptible double population Despite absence breakpoints epidermidis, may be an option treatment complex BJI, including ≤0.094 mg/L, leading 64% susceptibility. This underlines importance determining specific management BJI material.